Evidence map›Paper›PMID 42909357›Full record

ArticleNAR molecular medicine2026

Identification of small-molecule inhibitors of the immune system repressor Regnase-1.

Arthur Millius, Chee-Hong Takahiro Yew, Yuko Misumi, Jian Yu, Daisuke Takaya, Shuhei Miyakawa, Eun-Sol Choi, Hyo-Jun Lee, Tatum Melati Andini, Fahad Khalaf and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NAR molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Arthur MilliusDepartment of Genome Informatics, Research Institute for Microbial Diseases (RIMD), The University of Osaka, 565-0871Osaka, Japan.ORCID https://orcid.org/0000-0002-5280-6730
Chee-Hong Takahiro YewDepartment of Genome Informatics, Research Institute for Microbial Diseases (RIMD), The University of Osaka, 565-0871Osaka, Japan.ORCID https://orcid.org/0000-0002-8735-0665
Yuko MisumiTechnoPro, Inc. TechnoPro R&D, Company, 650-0047Kobe, Japan.
Jian YuProtein Crystallography Laboratory, Institute for Protein Research, The University of Osaka, 565-0871Osaka, Japan.ORCID https://orcid.org/0000-0003-2854-9225
Daisuke TakayaGraduate School of Pharmaceutical Sciences, The University of Osaka, 565-0871Osaka, Japan.ORCID https://orcid.org/0000-0001-6020-8151
Shuhei MiyakawaGraduate School of Pharmaceutical Sciences, The University of Osaka, 565-0871Osaka, Japan.ORCID https://orcid.org/0009-0005-6275-5550
Eun-Sol ChoiDepartment of Chemistry, Kunsan National University, 54150Gunsan, Republic of Korea.
Hyo-Jun LeeDepartment of Chemistry, Kunsan National University, 54150Gunsan, Republic of Korea.ORCID https://orcid.org/0000-0001-6790-5160
Tatum Melati AndiniDepartment of Genome Informatics, Research Institute for Microbial Diseases (RIMD), The University of Osaka, 565-0871Osaka, Japan.ORCID https://orcid.org/0009-0001-7865-2506
Fahad KhalafDepartment of Genome Informatics, Research Institute for Microbial Diseases (RIMD), The University of Osaka, 565-0871Osaka, Japan.ORCID https://orcid.org/0009-0009-3677-8774
Kazuhiko MaedaLaboratory of Host Defense, WPI-iFReC, The University of Osaka, 565-0871Osaka, Japan.ORCID https://orcid.org/0000-0003-0305-8163
Kaori FukuzawaGraduate School of Pharmaceutical Sciences, The University of Osaka, 565-0871Osaka, Japan.ORCID https://orcid.org/0000-0001-5357-8250
Genji KurisuProtein Crystallography Laboratory, Institute for Protein Research, The University of Osaka, 565-0871Osaka, Japan.ORCID https://orcid.org/0000-0002-5354-0807
Shizuo AkiraLaboratory of Host Defense, WPI-iFReC, The University of Osaka, 565-0871Osaka, Japan.ORCID https://orcid.org/0000-0001-7602-9617
Soyoung ParkLaboratory for Systems Immunology, Immunology Frontier Research Center (WPI-iFReC), The University of Osaka, 565-0871Osaka, Japan.ORCID https://orcid.org/0000-0001-7855-1302
Daron M StandleyDepartment of Genome Informatics, Research Institute for Microbial Diseases (RIMD), The University of Osaka, 565-0871Osaka, Japan.ORCID https://orcid.org/0000-0003-4078-0817

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Regnase-1 is an essential RNase that suppresses immune cell activation by targeting the mRNA of pro-inflammatory cytokines such as interleukin 6 (IL-6). Although genetic inhibition of Regnase-1 activity in CD8+ T cells has been shown to enhance antitumor immunity, no molecular inhibitors of Regnase-1 have been reported. By exploiting a library of nucleic acid analogs in conjunction with an RNA displacement assay, we identified multiple candidate competitors of Regnase-1 RNA substrates. Among these, suramin-an approved drug for treating African sleeping sickness-and several of its derivatives displaced Regnase-1 RNA targets with submicromolar affinity, competitively inhibited Regnase-1-mediated degradation of RNA

Identifiers

PMID42909357
PMCPMC13684271

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.